We investigated the use of intravenous iron by women of reproductive age, analysing dispensing data for a 10% random sample of Australians eligible to receive subsidised medicines under the Pharmaceutical Benefits Scheme (PBS).3 We included data for all women aged 18–44 years with a dispensing claim for intravenous iron during January 2013 to December 2017. Three preparations were available: iron polymaltose and iron sucrose during 2013–2017, and ferric carboxymaltose from June 2014. We calculated the annual number and rate of intravenous iron dispensing claims and iron preparation types by age group, using Australian Bureau of Statistics 2017 population data,4 and estimated overall dispensing rates by extrapolating these numbers to the national level (Supporting Information). The study was approved by the New South Wales Population and Health Services Research Ethics Committee (reference, 2013/11/494) and the federal Department of Human Services External Request Evaluation Committee.
- Iron deficiency anemias
- Population health
- Women’s health
Shand, A. W., Bell, J., Henry, A., Grzeskowiak, L. E., Kidson-Gerber, G., Pearson, S., & Nassar, N. (2020). Rapid increase in intravenous iron therapy for women of reproductive age in Australia. Medical Journal of Australia, 213(2), 85-86. https://doi.org/10.5694/mja2.50618